Rationale for Complementary Targeting & Peptide Nucleic Acid Oligonucleotide Delivery for Allele-Specific Targeting of KRAS G12D

Time: 9:50 am
day: Day One


  • Reviewing preceding delivery strategies and efforts for improvements rendered to cationic-aliphatic components
  • Proof of principle: In Vitro and In Vivo targeting of BRAF V600E oncogene
  • In vitro studies showing allele-specific targeting of the KRAS G12D oncogene and a nar complete suppression of KRAS G12D transcription, allele-specifically
  • Outlining the downstream suppression of signaling pathways and allele-specific suppression of RAS-altered MEFs